It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Breast cancer is one of leading causes of death worldwide in the female population. Deaths from breast cancer could be reduced significantly through earlier and more efficient detection of the disease. Saliva, an oral fluid that contains an abundance of protein biomarkers, has been recognized as a promising diagnostic biofluid that is easy to isolate through non-invasive techniques. Assays on saliva can be performed rapidly and are cost-effective. Therefore, our work aimed to identify salivary biomarkers present in the initial stages of breast cancer, where cell alterations are not yet detectable by histopathological analysis. Using state-of-the-art techniques, we employed a transgenic mouse model of mammary cancer to identify molecular changes in precancerous stage breast cancer through protein analysis in saliva. Through corroborative molecular approaches, we established that proteins related to metabolic changes, inflammatory process and cell matrix degradation are detected in saliva at the onset of tumor development. Our work demonstrated that salivary protein profiles can be used to identify cellular changes associated with precancerous stage breast cancer through non-invasive means even prior to biopsy-evident disease.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Federal University of Minas Gerais, Department of Pathology, Belo Horizonte, Brazil (GRID:grid.8430.f) (ISNI:0000 0001 2181 4888)
2 Cruzeiro do Sul University, Post Graduate Program in Dentistry, São Paulo, Brazil (GRID:grid.411936.8) (ISNI:0000 0001 0366 4185)
3 Hospital Israelita Albert Einstein, São Paulo, Brazil (GRID:grid.413562.7) (ISNI:0000 0001 0385 1941)
4 University of São Paulo, Institute of Biomedical Sciences, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722)
5 Instituto Butantan, Laboratory of Applied Toxicology, Center of Toxins, Immune-Response and Cell Signaling (LETA/CeTICS), São Paulo, Brazil (GRID:grid.418514.d) (ISNI:0000 0001 1702 8585)
6 State University of New York, Department of Oral Biology, School of Dental Medicine, The University of Buffalo, Buffalo, USA (GRID:grid.273335.3) (ISNI:0000 0004 1936 9887)
7 Federal University of Minas Gerais, Department of Pathology, Belo Horizonte, Brazil (GRID:grid.8430.f) (ISNI:0000 0001 2181 4888); University of Wisconsin-Madison, Department of Dermatology, Medical Sciences Center, Madison, USA (GRID:grid.14003.36) (ISNI:0000 0001 2167 3675); Columbia University Medical Center, Department of Radiology, New York, USA (GRID:grid.239585.0) (ISNI:0000 0001 2285 2675)
8 Cruzeiro do Sul University, Post Graduate Program in Dentistry, São Paulo, Brazil (GRID:grid.411936.8) (ISNI:0000 0001 0366 4185); Hospital Israelita Albert Einstein, São Paulo, Brazil (GRID:grid.413562.7) (ISNI:0000 0001 0385 1941); Department of Periodontology, University of Texas Health Science Center San Antonio, San Antonio, USA (GRID:grid.267309.9) (ISNI:0000 0001 0629 5880)